Henk-Jan Guchelaar
Overview
Explore the profile of Henk-Jan Guchelaar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
337
Citations
6941
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brokaar E, Knikman J, Visser L, van den Bos F, Henricks L, Lunenburg C, et al.
Fundam Clin Pharmacol
. 2025 Feb;
39(2):e70000.
PMID: 39969252
Background: Despite the implementation of DPYD genotype-guided dosing, approximately 1 in 3 patients receiving fluoropyrimidine-containing chemotherapy continues to experience severe toxicity. While clinical studies have demonstrated a favorable tolerance among...
2.
Manson L, Anholts J, Drabbels J, Swen J, Roelen D, Guchelaar H
Pharmacogenomics J
. 2025 Feb;
25(2):1.
PMID: 39966354
Patients carrying specific HLA risk alleles are at higher risk for developing drug hypersensitivity reactions, yet pre-therapeutic screening is uncommon. We examined whether patients with a history of drug allergies...
3.
Shadid I, Brustad N, Chawes B, Moes D, Weiss S, Guchelaar H, et al.
Biomed Pharmacother
. 2025 Jan;
183:117859.
PMID: 39874780
Gestational 25-hydroxyvitamin D (25[OH]D) is important in fetal lung development and may influence offspring respiratory outcomes, making accurate exposure assessment essential to understand clinical associations. Therefore, we used the combined...
4.
Wolthuis D, Nijenhuis M, Soree B, de Boer-Veger N, Buunk A, Guchelaar H, et al.
Eur J Hum Genet
. 2024 Dec;
PMID: 39676086
Aligned with the mission of the Dutch Pharmacogenetics Working Group (DPWG) to promote the implementation of pharmacogenetics (PGx), this guideline is specifically designed to optimize pharmacotherapy of cholesterol lowering medication...
5.
Roncato R, Bignucolo A, Peruzzi E, Montico M, De Mattia E, Foltran L, et al.
JAMA Netw Open
. 2024 Dec;
7(12):e2449441.
PMID: 39641926
Importance: To date, the clinical benefit and utility of implementing a DPYD/UGT1A1 pharmacogenetic-informed therapy with fluoropyrimidines and/or irinotecan have not been prospectively investigated. Objective: To examine clinically relevant toxic effects,...
6.
Yin A, de Groot F, Guchelaar H, Nijland M, Doorduijn J, Touw D, et al.
Clin Pharmacokinet
. 2024 Dec;
64(1):79-91.
PMID: 39625585
Background: High-dose methotrexate (HD-MTX)-based polychemotherapy is widely used for patients with central nervous system (CNS) lymphoma. The pharmacokinetic (PK) variability and unpredictable occurrence of toxicity remain major concerns in HD-MTX...
7.
Knikman J, Zhai Q, Lunenburg C, Henricks L, Bohringer S, van der Lee M, et al.
Genome Med
. 2024 Aug;
16(1):101.
PMID: 39148102
Background: The Alpe-DPD study (NCT02324452) demonstrated that prospective genotyping and dose-individualization using four alleles in DPYD (DPYD*2A/rs3918290, c.1236G > A/rs75017182, c.2846A > T/rs67376798 and c.1679 T > G/rs56038477) can mitigate...
8.
Shadid I, Guchelaar H, Weiss S, Mirzakhani H
Life Sci
. 2024 Aug;
355:122942.
PMID: 39134205
Vitamin D's role in mineral homeostasis through its endocrine function, associated with the main circulating metabolite 25-hydroxyvitamin D, is well characterized. However, the increasing recognition of vitamin D's paracrine and...
9.
Bouwman H, Guchelaar H
Drug Discov Today
. 2024 Aug;
29(9):104134.
PMID: 39111540
Eculizumab is an orphan drug with indications for extremely rare autoimmune disorders. It is primarily prescribed for use in patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; but...
10.
Klomp S, Veringa A, Alffenaar J, de Boer M, Span L, Guchelaar H, et al.
Clin Transl Sci
. 2024 Jul;
17(7):e13887.
PMID: 39010708
Voriconazole is the cornerstone of the treatment and prevention of fungal infections. While there is a good correlation between CYP2C19 genotype and voriconazole exposure during prophylactic treatment, no correlation was...